Letter: PCSK9 inhibitor for liver transplant patients during the post-statin era?

Aliment Pharmacol Ther. 2023 Jan;57(1):185-186. doi: 10.1111/apt.17258.

Authors

Jiamei Wang^{1

2}, Jia Wu³, Zhiqing He^{1

2}, Haiguang Xin⁴

Affiliations

¹ Department of Cardiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
² Shanghai Cardiovascular Institute of Integrative Medicine, Shanghai, China.
³ Department of Health Management Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
⁴ Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

PMID: 36480716
DOI: 10.1111/apt.17258

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Liver Transplantation* / adverse effects
Proprotein Convertase 9

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
Antiviral Agents